Literature DB >> 2569172

Studies on the conditions determining the inhibitory effect of somatostatin on adrenocorticotropin, prolactin and thyrotropin release by cultured rat pituitary cells.

S W Lamberts1, J Zuyderwijk, F den Holder, P van Koetsveld, L Hofland.   

Abstract

UNLABELLED: Somatostatin (SRIH) is a physiological inhibitor of growth hormone (GH) secretion, but its role in the regulation of adrenocorticotropic hormone (ACTH), prolactin (PRL) and thyroid-stimulating hormone (TSH) release is unclear. SRIH (1 pM to 1 microM) did not affect basal and corticotropin-releasing hormone (CRH)-stimulated ACTH release by normal rat pituitary cells cultured in medium with 10% fetal calf serum (FCS). In cells deprived of serum for 48 h, or preincubated with the glucocorticoid-receptor-blocking agent, RU 38486, CRH-stimulated ACTH release was significantly suppressed by 1 pM to 0.10 nM SRIH. Preincubation with 5 nM dexamethasone completely abolished this inhibitory effect of SRIH on ACTH release. PRL release by pituitary cells cultured in phenol red-free culture medium with 10% estrogen-stripped FCS showed a very low sensitivity to SRIH. Increasing concentrations of 10 and 50 pM and 1 nM estradiol made PRL release by these cells significantly less sensitive to 50 nM dopamine, whereas the sensitivity to SRIH increased to a similar extent. In all instances dopamine and SRIH together exerted additive inhibitory effects, the extent of which remained similar under all conditions. After a 2-hour incubation, thyrotropin-releasing hormone-stimulated TSH secretion was significantly suppressed by 100 nM and 1 microM SRIH only in cells cultured in medium with 10% hypothyroid serum, and not in cells cultured in medium with 10% FCS. Such a difference in the sensitivity of thyrotrophs to SRIH disappeared during longer incubation.
CONCLUSIONS: (1) ACTH release by normal corticotrophs is only sensitive to SRIH in the absence of the physiological peripheral feedback regulation by glucocorticoids.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2569172     DOI: 10.1159/000125200

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  13 in total

Review 1.  Molecular basis of pharmacological therapy in Cushing's disease.

Authors:  Diego Ferone; Claudia Pivonello; Giovanni Vitale; Maria Chiara Zatelli; Annamaria Colao; Rosario Pivonello
Journal:  Endocrine       Date:  2013-11-23       Impact factor: 3.633

Review 2.  Complications of acromegaly: thyroid and colon.

Authors:  Amit Tirosh; Ilan Shimon
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

Review 3.  The role of somatostatin analogs in Cushing's disease.

Authors:  Joost van der Hoek; Steven W J Lamberts; Leo J Hofland
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

4.  The effects of octreotide in a patient with Nelson's syndrome.

Authors:  F Kelestimur; C Utas; O Ozbakir; A Selçuklu; O Kandemir; N Ozcan
Journal:  Postgrad Med J       Date:  1996-01       Impact factor: 2.401

5.  Calcitonin inhibits prolactin gene transcription in rat pituitary cells.

Authors:  Q Xue-Zhang; S M Stanley; G V Shah
Journal:  Endocrine       Date:  1995-06       Impact factor: 3.633

6.  Treatment of Cushing disease: overview and recent findings.

Authors:  Tatiana Mancini; Teresa Porcelli; Andrea Giustina
Journal:  Ther Clin Risk Manag       Date:  2010-10-21       Impact factor: 2.423

Review 7.  Drugs that suppress TSH or cause central hypothyroidism.

Authors:  Bryan R Haugen
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2009-12       Impact factor: 4.690

8.  Comparative distribution of somatostatin and somatostatin receptors in PTU-induced hypothyroidism.

Authors:  Sneha Singh; Rishi K Somvanshi; Vandana Panda; Ujendra Kumar
Journal:  Endocrine       Date:  2020-04-25       Impact factor: 3.633

Review 9.  Somatostatin and dopamine receptors as targets for medical treatment of Cushing's Syndrome.

Authors:  C de Bruin; R A Feelders; S W J Lamberts; L J Hofland
Journal:  Rev Endocr Metab Disord       Date:  2008-07-19       Impact factor: 6.514

10.  Failure of somatostatin and octreotide to acutely affect the hypothalamic-pituitary-adrenal function in patients with corticotropin hypersecretion.

Authors:  B Ambrosi; D Bochicchio; C Fadin; P Colombo; G Faglia
Journal:  J Endocrinol Invest       Date:  1990-03       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.